Published in Gene Therapy Weekly, May 8th, 2003
"Thirty HLA-A2+ women with metastatic breast cancer received up to 14 vaccinations with MDA-MB-231-CD80, an HLA-A2+ allogeneic breast cancer cell line, which had been lipofected with the cDNA for the CD80 costimulatory molecule. Tumor cells were administered with BCG or GM-CSF as an adjuvant. Sera obtained before and after vaccination were analyzed for antibodies to tumor cell lysate, MUC1, HER2/neu and p53," scientists in the United States and the Netherlands report.
"Since the cell line was grown in fetal bovine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-05-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.